Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.67 |
| ▸ | CA2 | P00918 | 1/20 | 0.67 |
| ▸ | CA4 | P22748 | 1/20 | 0.67 |
| ▸ | CA6 | P23280 | 1/20 | 0.67 |
| ▸ | CA7 | P43166 | 1/20 | 0.67 |
| ▸ | TPMT | P51580 | 1/20 | 0.67 |
| ▸ | CA9 | Q16790 | 1/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.67 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.59 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.58 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TTR | P02766 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30683868 | 1.00 | TSHR (0.69) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL5492174 | 0.95 | TSHR (0.76) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL88998 | 0.94 | CA12 (0.67) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL8122418 | 0.94 | TSHR (0.78) | TSHRCA12CA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL3372494 | 0.92 | CA12 (0.65) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL6939685 | 0.92 | TSHR (0.71) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL21614005 | 0.92 | TSHR (0.76) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL8085474 | 0.90 | TSHR (0.78) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL13461276 | 0.88 | PLA2G4B (0.58) | TSHRPLA2G4B | |
| SCHEMBL1750327 | 0.88 | TSHR (0.74) | TSHRCA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117136187-A | Novel anti-hepatitis B compound | 上海齐鲁制药研究中心有限公司 | 2023-11-28 | — | — | CN | disclosed |
| WO-2022268154-A1 | NEW ANTI-HEPATITIS B COMPOUND | 上海齐鲁制药研究中心有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | TSHR 1095/4885CA12 2906/4885CA1 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.